Cagrilintide vs Semaglutide

Cagrilintide is an experimental long-acting amylin-like drug still in development, with no FDA approvals yet. Semaglutide is an FDA-approved GLP-1 receptor agonist sold under brand names like Ozempic and Wegovy, used to treat type 2 diabetes, obesity, chronic kidney disease, and cardiovascular risk. The main practical difference is that semaglutide is already on the market, while cagrilintide is still being studied. Both are taken as injections, but semaglutide also comes in a pill form (Rybelsus).

AI summary of the sources below.